Innovación, terapia y desarrollo farmacéutico en oftalmología
INNOFTAL
![Foto de Innovación, terapia y desarrollo farmacéutico en oftalmología](/img/grupo.png)
![Foto de Hospital del Mar](/img/noimage_org.png)
Hospital del Mar
Barcelona, EspañaPublicacións en colaboración con investigadores/as de Hospital del Mar (6)
2023
-
Anti-TNF vs tocilizumab in refractory uveitic cystoid macular edema due to Behcet's disease. Multicenter study of 49 patients
Seminars in Arthritis and Rheumatism, Vol. 58
-
SER recommendations for the treatment of uveitis
Reumatologia Clinica, Vol. 19, Núm. 9, pp. 465-477
2021
-
Long-term Follow-up and optimization of infliximab in refractory uveitis due to Behçet Disease: National study of 103 white patients
Journal of Rheumatology, Vol. 48, Núm. 5, pp. 741-750
2020
-
Biologic therapy in severe and refractory peripheral ulcerative keratitis (PUK). Multicenter study of 34 patients
Seminars in Arthritis and Rheumatism, Vol. 50, Núm. 4, pp. 608-615
2019
-
Anti-IL6-Receptor Tocilizumab in Refractory and Noninfectious Uveitic Cystoid Macular Edema: Multicenter Study of 25 Patients
American Journal of Ophthalmology, Vol. 200, pp. 85-94
-
Comparative Study of Infliximab Versus Adalimumab in Refractory Uveitis due to Behçet's Disease: National Multicenter Study of 177 Cases
Arthritis and Rheumatology, Vol. 71, Núm. 12, pp. 2081-2089